201 related articles for article (PubMed ID: 20553613)
41. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
42. Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background.
Eisold S; Ryschich E; Linnebacher M; Giese T; Nauheimer D; Wild A; Bartsch DK; Büchler MW; Schmidt J
Cancer; 2004 May; 100(9):1978-86. PubMed ID: 15112280
[TBL] [Abstract][Full Text] [Related]
43. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
[TBL] [Abstract][Full Text] [Related]
44. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
45. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
[TBL] [Abstract][Full Text] [Related]
46. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
47. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
Bi YL; Min M; Shen W; Liu Y
Tumour Biol; 2016 Nov; 37(11):15145-15155. PubMed ID: 27677287
[TBL] [Abstract][Full Text] [Related]
48. Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes.
Ku JL; Kim KH; Choi JS; Jeon YK; Kim SH; Shin YK; Kim TY; Bang YJ; Kim WH; Park JG
Cell Oncol (Dordr); 2011 Feb; 34(1):45-54. PubMed ID: 21290211
[TBL] [Abstract][Full Text] [Related]
49. PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.
Mahmood SF; Gruel N; Nicolle R; Chapeaublanc E; Delattre O; Radvanyi F; Bernard-Pierrot I
Am J Pathol; 2013 Nov; 183(5):1634-1644. PubMed ID: 24051013
[TBL] [Abstract][Full Text] [Related]
50. Establishment of a highly metastatic model with a newly isolated lung adenocarcinoma cell line.
Cui YQ; Geng Q; Yu T; Zhang FL; Lin HC; Li J; Zhu MX; Liu L; Yao M; Yan MX
Int J Oncol; 2015 Sep; 47(3):927-40. PubMed ID: 26134302
[TBL] [Abstract][Full Text] [Related]
51. The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.
Maity G; Haque I; Ghosh A; Dhar G; Gupta V; Sarkar S; Azeem I; McGregor D; Choudhary A; Campbell DR; Kambhampati S; Banerjee SK; Banerjee S
J Biol Chem; 2018 Mar; 293(12):4334-4349. PubMed ID: 29414775
[TBL] [Abstract][Full Text] [Related]
52. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
53. Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells.
Satoh K; Hamada S; Kimura K; Kanno A; Hirota M; Umino J; Fujibuchi W; Masamune A; Tanaka N; Miura K; Egawa S; Motoi F; Unno M; Vonderhaar BK; Shimosegawa T
Am J Pathol; 2008 Apr; 172(4):926-39. PubMed ID: 18349132
[TBL] [Abstract][Full Text] [Related]
54. α1,6-Fucosyltransferase contributes to cell migration and proliferation as well as to cancer stemness features in pancreatic carcinoma.
Liang C; Fukuda T; Isaji T; Duan C; Song W; Wang Y; Gu J
Biochim Biophys Acta Gen Subj; 2021 Jun; 1865(6):129870. PubMed ID: 33571582
[TBL] [Abstract][Full Text] [Related]
55. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
56. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
[TBL] [Abstract][Full Text] [Related]
57. Synthetic 8-hydroxydeoxyguanosine inhibited metastasis of pancreatic cancer through concerted inhibitions of ERM and Rho-GTPase.
Park JM; Han YM; Jeong M; Chung MH; Kwon CI; Ko KH; Hahm KB
Free Radic Biol Med; 2017 Sep; 110():151-161. PubMed ID: 28602912
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3.
Li Z; Li X; Yu C; Wang M; Peng F; Xiao J; Tian R; Jiang J; Sun C
Tumour Biol; 2014 Dec; 35(12):11751-9. PubMed ID: 25344675
[TBL] [Abstract][Full Text] [Related]
59. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
[TBL] [Abstract][Full Text] [Related]
60. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
